# Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)

> **NCT00154102** · PHASE3 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 1221 (actual)

## Conditions studied

- Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)

## Key facts

- **NCT ID:** NCT00154102
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2006-12
- **Final completion:** 2011-03
- **Target enrollment:** 1221 (ACTUAL)
- **Last updated:** 2017-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00154102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00154102, "Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00154102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*